Generation Bio Co (NASDAQ:GBIO) specializes in developing genetic medicines with a focus on durable, scalable delivery for patients globally. Its innovative approach aims at leveraging non-viral drug delivery systems to address a broad range of serious diseases. The company's projects revolve around its proprietary non-viral gene therapy platform, which seeks to overcome the limitations of current treatments by offering potential for re-dosability and large-scale manufacturing. Generation Bio is committed to transforming the lives of patients by making gene therapy more accessible and effective. Through research and strategic collaborations, its objective is to expand its pipeline and bring transformative therapies from the lab to the clinic.